<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2027-0119</journal-id>
<journal-title><![CDATA[Urología Colombiana]]></journal-title>
<abbrev-journal-title><![CDATA[Urol. Colomb.]]></abbrev-journal-title>
<issn>2027-0119</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Colombiana de Urología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2027-01192024000200055</article-id>
<article-id pub-id-type="doi">10.24875/ruc.23000097</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Oncological outcomes in non-seminomatous testicular tumors and residual mass after cisplatin-based chemotherapy]]></article-title>
<article-title xml:lang="es"><![CDATA[Resultados oncológicos en tumores testiculars no seminomatosos y masa residual posquimioterapia con cisplatino]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ocampo-Gómez]]></surname>
<given-names><![CDATA[María A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Moreno-Matson]]></surname>
<given-names><![CDATA[María C.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Londoño]]></surname>
<given-names><![CDATA[David Ruiz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cabrera]]></surname>
<given-names><![CDATA[Marino]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Varela]]></surname>
<given-names><![CDATA[Rodolfo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad del Rosario School of Medicine and Health Sciences Department of Urology]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,olombian National Cancer Institute Department of Urology ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2024</year>
</pub-date>
<volume>33</volume>
<numero>2</numero>
<fpage>55</fpage>
<lpage>60</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S2027-01192024000200055&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S2027-01192024000200055&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S2027-01192024000200055&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: The aim of our study is to describe the progression-free survival (PFS) in patients with clinical stage (CS) II and IIINSGCT with an RM after primary or secondary CT with negative serum markers (NSM). A residual mass (RM) in non-seminomatous germ cell tumors (NSGCT) after chemotherapy (CT) is defined as a mass &gt;1 cm in greatest diameter. The pre ferred treatment for RM is retroperitoneal lymph node dissection (RPLND), with a cure rate greater than 80%.  Methods: We identified 60 patients with NSGCT, RM, and NSM between 2007 and 2020. Data regarding clinical and oncological outcomes as well as pathological information were obtained in a retrospective fashion from our electronic database.  Results: A total of 60 patients were included. 50% of cases were CS II, and 50% CS III. About 90% of the patients had undergone RPLND. Teratoma was found in 73.6% of these patients. PFS and OS were better in CS II patients, compared to CS III. The patients treated with observation were found to have a shorter PFS compared to patients who underwent RPLND. Patients with viable tumors after RPLND had shorter OS compared to patients with teratoma and fibrosis.  Conclusions: RPLND continues to be the treatment of choice to patients with RM after CT and NSM.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Nuestro objetivo es describir la supervivencia libre de progresión (SLP) en pacientes con TCGNS en estadio clínico (CS) II y III con masa residual tras QT primaria o secundaria con marcadores séricos negativos (MSN).  Métodos: Se incluyeron pacientes con TCGNS, MR y MSN atendidos entre 2007-2020. Los datos se obtuvieron de forma retrospectiva de nuestra base de datos electrónica.  Resultados: Se identificaron 60 pacientes, el 50% eran CS II y el 50% CS III, y el 90% de los pacientes fueron sometidos a DGLRP. Se evidenció teratoma en el 73,6% de los pacientes. La SLP y la super vivencia global (SG) fue mejor en pacientes con CS II, frente a CS III. Los pacientes observados tuvieron una SLP menor frente a los que se sometieron a DGLRP. Los pacientes tratados con DGLRP y evidencia de tumor viable en la patología tenían una SG más corta comparado con teratoma y fibrosis.  Conclusión: La DGLRP sigue siendo el tratamiento de elección para las MR posterior a QT y MSN.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Non seminomatous testicular tumor]]></kwd>
<kwd lng="en"><![CDATA[Residual mass]]></kwd>
<kwd lng="en"><![CDATA[Cisplatin based chemotherapy]]></kwd>
<kwd lng="es"><![CDATA[Tumor testicular no seminomatoso]]></kwd>
<kwd lng="es"><![CDATA[Masa residual]]></kwd>
<kwd lng="es"><![CDATA[Quimioterapia basada en cisplatino]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Öztürk]]></surname>
<given-names><![CDATA[Ç]]></given-names>
</name>
<name>
<surname><![CDATA[Been]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Van Ginkel]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gietema]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Hoekstra]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Laparos copic resection of residual retroperitoneal tumor mass in advanced non-seminomatous testicular germ cell tumors; a feasible and safe oncological procedure]]></article-title>
<source><![CDATA[Sci Rep.]]></source>
<year>2019</year>
<volume>9</volume>
<page-range>15837</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Steyerberg]]></surname>
<given-names><![CDATA[EW]]></given-names>
</name>
<name>
<surname><![CDATA[Keizer]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Habbema]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prediction models for the histology of residual masses after chemotherapy for metastatic testicular cancer. ReHiT Study Group]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>1999</year>
<volume>83</volume>
<page-range>856-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Luz]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Kotb]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Aldousari]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Brimo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Tanguay]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kassouf]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Retroperitoneal lymph node dissection for residual masses after chemo therapy in nonseminomatous germ cell testicular tumor]]></article-title>
<source><![CDATA[World J Surg Oncol]]></source>
<year>2010</year>
<volume>8</volume>
<page-range>97</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carver]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Shayegan]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Serio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Motzer]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bosl]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sheinfeld]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2007</year>
<volume>25</volume>
<page-range>1033-7</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Altan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Haberal]]></surname>
<given-names><![CDATA[HB]]></given-names>
</name>
<name>
<surname><![CDATA[Aççi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Güdeloglu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dogrul]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Yazici]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Determination of risk factors for progression in patients with viable tumor at post-chemotherapy lymph node dissection due to disseminated non-seminomatous germ-cell tumors]]></article-title>
<source><![CDATA[Int J Clin Oncol]]></source>
<year>2020</year>
<volume>26</volume>
<page-range>186-91</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bhanvadia]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bagrodia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Eggener]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lymph node count impacts survival following post-chemotherapy retroperitoneal lymphadenectomy for non-seminomatous testicular cancer: a population-based analysis]]></article-title>
<source><![CDATA[BJU Int]]></source>
<year>2019</year>
<volume>124</volume>
<page-range>792-800</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parekh]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fitzgerald]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Ercole]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of post-chemotherapy residual mass in patients with metastatic nonseminomatous germ cell tumors of the testis]]></article-title>
<source><![CDATA[Indian J Urol.]]></source>
<year>2010</year>
<volume>26</volume>
<page-range>98-101</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beck]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Foster]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Bihrle]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Donohue]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Einhorn]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor?]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2007</year>
<volume>110</volume>
<page-range>1235-40</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Foster]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Donohue]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Can retroperitoneal lymphadenectomy be omi tted in some patients after chemotherapy?]]></article-title>
<source><![CDATA[Urol Clin North Am]]></source>
<year>1998</year>
<volume>25</volume>
<page-range>479-84</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[King]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kawakami]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Heng]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Loo Gan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Post-chemotherapy retroperitoneal lymph node dissection for non-seminomatous germ cell tumors: a single-surgeon, Canadian experience]]></article-title>
<source><![CDATA[Can Urol Assoc.]]></source>
<year>2020</year>
<volume>14</volume>
<page-range>E407-11</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nowroozi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ayati]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Arbab]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jamshidian]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ghorbani]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Niroomand]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Postchemotherapy retroperitoneal lymph node dissection in patients with nonseminomatous testicular cancer: a single center experiences]]></article-title>
<source><![CDATA[Nephrourol Mon.]]></source>
<year>2015</year>
<volume>7</volume>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Napier]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Naraghi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Christmas]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rustin]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term follow-up of residual masses after chemotherapy in patients with non-seminomatous germ cell tumors]]></article-title>
<source><![CDATA[Br J Cancer]]></source>
<year>2000</year>
<volume>83</volume>
<page-range>1274-80</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sheinfeld]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bajorin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of the postchemotherapy residual mass]]></article-title>
<source><![CDATA[Urol Clin North Am]]></source>
<year>1993</year>
<volume>20</volume>
<page-range>133-43</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oechsle]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hartmann]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brenner]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Venz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Weissbach]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Franzius]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[[18F]fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group]]></article-title>
<source><![CDATA[J Clin Oncol.]]></source>
<year>2008</year>
<volume>26</volume>
<page-range>5930-5</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Steyerberg]]></surname>
<given-names><![CDATA[EW]]></given-names>
</name>
<name>
<surname><![CDATA[Keizer]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fossa]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Sleijfer]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[Toner]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Schraffordt Koops]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups]]></article-title>
<source><![CDATA[J Clin Oncol.]]></source>
<year>1995</year>
<volume>13</volume>
<page-range>1177-87</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Debono]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Heilman]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
<name>
<surname><![CDATA[Einhorn]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Donohue]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors]]></article-title>
<source><![CDATA[J Clin Oncol.]]></source>
<year>1997</year>
<volume>15</volume>
<page-range>1455-64</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stephens]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Gonin]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hutchins]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
<name>
<surname><![CDATA[Einhorn]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Positron emission tomography evaluation of residual radiographic abnormalities in postche motherapy germ cell tumor patients]]></article-title>
<source><![CDATA[J Clin Oncol.]]></source>
<year>1996</year>
<volume>14</volume>
<page-range>1637-41</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Strauss]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Ponti]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The applications of PET in clinical oncology]]></article-title>
<source><![CDATA[J Nucl Med]]></source>
<year>1991</year>
<volume>32</volume>
<page-range>623-48</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johns Putra]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lawrentschuk]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ballok]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[18F-fluorodeoxyglucose posi tron emission tomography in evaluation of germ cell tumor after chemo therapy]]></article-title>
<source><![CDATA[Urology]]></source>
<year>2004</year>
<volume>64</volume>
<page-range>1202-7</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
